Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.


Armstrong A. J., Saad F., Oya M., Vianna K., Özgüroğlu M., Gedye C., ...Daha Fazla

European urology oncology, cilt.9, sa.1, ss.80-92, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1016/j.euo.2025.09.010
  • Dergi Adı: European urology oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.80-92
  • Anahtar Kelimeler: Abiraterone, Brief Pain Inventory-Short Form, Functional Assessment of Cancer Therapy-Prostate, Health-related quality of life, Metastatic castration-resistant prostate cancer, Olaparib, Patient-reported outcomes, PROpel trial
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet